Previous studies have validated that the m6A score could be a credible biomarker for predicting the efficacy of anti-PD-1/L1 immunotherapy in different types of tumours such as melanoma, breast cancer and colorectal cancer. This evidence concerns the gene PDCD1 and breast cancer.